Products for Research Use Only
RegisterLogin

Ranolazine

CAT: 0804-HY-B0280-01Size: 100 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-B0280-01Size:100 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Ranolazine (CVT 303) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) [1][2]. Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor[3]. Antianginal agent.
CAS Number
95635-55-5
Product Name Alternative
CVT 303; RS 43285-003
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Calcium Channel; Sodium Channel
Type
Reference compound
Related Pathways
Membrane Transporter/Ion Channel; Neuronal Signaling
Applications
COVID-19-immunoregulation
Field of Research
Cardiovascular Disease; Cancer
Assay Protocol
https://www.medchemexpress.com/ranolazine.html
Purity
99.79
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(NC1=C(C)C=CC=C1C)CN2CCN(CC(O)COC3=CC=CC=C3OC)CC2
Molecular Formula
C24H33N3O4
Molecular Weight
427.54
Precautions
H302, H315, H319, H335
References & Citations
[1]Keating GM. Ranolazine: a review of its use as add-on therapy in patients with chronic stable angina pectoris. Drugs. 2013 Jan;73 (1) :55-73.|[2]Wang WQ, et al. Antitorsadogenic effects of ({+/-}) -N- (2,6-dimethyl-phenyl) - (4[2-hydroxy-3- (2-methoxyphenoxy) propyl]-1-piperazine (ranolazine) in anesthetized rabbits. J Pharmacol Exp Ther. 2008 Jun;325 (3) :875-81.|[3]Zacharowski K, et al. Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat. Eur J Pharmacol. 2001 Apr 20;418 (1-2) :105-10.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Citation 01
Philos Trans R Soc Lond B Biol Sci. 2023 Jun 19;378 (1879) :20220163.|J Invest Dermatol. 2023 Feb;143 (2) :305-316.e5.|Pharmaceutics. 2024 May 29;16 (6) :728.|Theranostics. 2018 Oct 29;8 (19) :5452-5468.

Alternative Products

CatalogName
A8510-5.1Ranolazine

Popular Products